| Accreditation
Statement: This activity has been planned and implemented in
accordance with the Essential Areas and Policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
sponsorship of the Dannemiller Memorial Educational Foundation and
the France Foundation. The Dannemiller Memorial Educational Foundation
is accredited by the ACCME to provide continuing medical education
for physicians.
Credit
Designation Statement: The Dannemiller Memorial Educational
Foundation designates this educational activity for up to 2.5
hours in category 1 credit towards the AMA Physician’s Recognition
Award. Each physician should claim only those hours of credit
that he/she actually spent in the educational activity.
Statement
of Need: Blockade of the Renal Angiotensin System (RAS) lowers
systemic blood pressure and intraglomerular pressure in hypertension
and chronic renal diseases. Studies suggest that use of angiotensin-converting
enzyme inhibitors (ACE inhibitors) is associated with a maximal
renoprotective effect when compared to conventional agents. Studies
have also demonstrated that interruption of the RAS axis using
drugs that interfere with the production or action of angiotensin
II reduces proteinuria and/or delays the progression of renal
disease in patients with diabetic and nondiabetic glomerular diseases.
Understanding the effect of the blockade of the RAS on intrarenal
hemodynamics and the pathophysiology of hypertension and diabetic
nephropathy is a must for every physician.
Goal:
To update physicians on the characteristics of the renin-angiotensin
system by ACE and non-ACE pathways, and its uptake and transport
in the kidney.
Intended
Audience: This activity has been developed for physicians
treating patients experiencing hypertension secondary to intrarenal
hemodynamics.
Faculty
Disclosures: The Dannemiller Memorial Educational Foundation
requires that the faculty participating in a continuing medical
education activity disclose to participants any significant financial
interest or other relationship (1) with the manufacturer(s) of
any commercial product(s) and/or provider(s) of commercial services
discussed in an educational presentation, and (2) with any commercial
supporters of the activity. The presenting faculty reported the
following:
Marc S. Weinberg,
MD, FACP, has received unrestricted educational grants and has
served as a consultant and lecturer for AstraZeneca, Merck &
Co. Inc., Pfizer Inc., and Bristol-Myers Squibb, whose products
may be discussed in this program.
L. Gabriel
Navar, PhD, has received research grants from AstraZeneca and
is a member of the Speakers Bureau at AstraZeneca, whose products
may be discussed in this program.
Naomi D. L.
Fisher, MD, receives research support from AstraZeneca, SmithKline
Beecham, and Bristol-Myers Squibb, whose products may be discussed
in this program.
Judith Miller,
MD, FRCP(C), MSc has nothing to disclose.
Jean-Marc
Lalouel, MD, DSc, has nothing to disclose.
Method
of Participation: This activity should take approximately
2.5 hours to complete. The participant should, in order, read
the objectives contained in this activity, read or listen to the
activity, answer the five-question, multiple-choice post-test,
and complete the registration/evaluation form that appears at
the end of this activity. This form provides each participant
the opportunity to comment on the extent to which educational
objectives were met, the quality of the instructional process,
the perception of enhanced professional effectiveness, the perception
of commercial bias, and their views on future educational needs.
To receive credit for this activity, follow the instructions provided
at the beginning of the post-test. This credit is valid through
December 31, 2001. No credit will be given after this date.
|
|
|
|
This
program is sponsored by
The Dannemiller Memorial Foundation and The France Foundation.
This was not part of the official 33rd Annual Meeting as
planned by the ASN Program Committee.
Supported by an unrestricted educational grant from AstraZeneca
LP.
|
|
